OC
PRME icon

Oppenheimer & Co’s Prime Medicine PRME Stock Holding History

Oppenheimer & Co’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Sell
29,650
-4,006
-12% -$13.3K ﹤0.01% 1717
2026
Q1 		$117K Buy
33,656
+21,223
+171% +$80.8K ﹤0.01% 1630
2025
Q4 		$43.1K Buy
+12,433
New +$55.3K ﹤0.01% 1516
2025
Q1 		– Sell
-12,106
Closed -$35.4K – 1635
2024
Q4 		$35.4K Sell
12,106
-5,765
-32% -$20.2K ﹤0.01% 1532
2024
Q3 		$69.2K Sell
17,871
-3,160
-15% -$14.6K ﹤0.01% 1471
2024
Q2 		$108K Buy
21,031
+855
+4% +$5.18K ﹤0.01% 1382
2024
Q1 		$141K Sell
20,176
-422
-2% -$3.2K ﹤0.01% 1374
2023
Q4 		$182K Sell
20,598
-939
-4% -$7.23K ﹤0.01% 1296
2023
Q3 		$205K Buy
21,537
+6,152
+40% +$79.9K ﹤0.01% 1259
2023
Q2 		$225K Buy
15,385
+267
+2% +$3.73K ﹤0.01% 1254
2023
Q1 		$186K Buy
15,118
+1,106
+8% +$18K ﹤0.01% 1269
2022
Q4 		$260K Buy
+14,012
New +$253K 0.01% 1134

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Oppenheimer & Co's PRME Position: Q2 2026 in Review

Oppenheimer & Co reduced its Prime Medicine (PRME) stake by 12% in Q2 2026, selling an estimated $13.3K and leaving 29,650 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #1717.

Oppenheimer & Co first reported a position in PRME in Q4 2022 and has held it in 12 quarters since. The position peaked at $260K in Q4 2022. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Oppenheimer & Co held 29,650 shares of Prime Medicine worth $109K as of Q2 2026.
  • Oppenheimer & Co sold 4,006 Prime Medicine shares in Q2 2026, an estimated $13.3K.
  • Prime Medicine made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1717 holding.
  • Oppenheimer & Co first reported a position in Prime Medicine in Q4 2022 and has held it in 12 quarters since.
  • Oppenheimer & Co's Prime Medicine position peaked at $260K in Q4 2022.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.